


Curriculum Vitae

Name	Makoto Naganuma	
Country	Japan	
Organization	Kansai Medical University	
Current Position	Professor	

Educational Background

1992 M.D. School of Medicine, Keio University, Tokyo, Japan
2002 Ph.D. School of Medicine, Keio University, Tokyo, Japan

Professional Experience

2012-2015 Assistant Professor Center for Diagnostic and Therapeutic Endoscopy
Keio University
2015.6-2017.5 Assistant Professor Department of Gastroenterology and Hepatology
Keio University
2017.6-2020. 4 Associate Professor Department of Gastroenterology and Hepatology
Keio University

Professional Organizations

The American Gastroenterological Association
The Japanese Society for Gastroenterology
The Japanese Society for Gastroenterological Endoscopy
The Japanese Society for Internal Medicine

Main Scientific Publications

- Naganuma M, Sugimoto S, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Suda W, Hattori M, Fukuda S, Hirayama A, Abe T, Watanabe M, Hibi T, Suzuki Y, Kanai T, for the INDIGO Study Group. Efficacy of Indigo naturalis in a Multicenter Randomized Controlled Trial of Patients with Ulcerative Colitis. *Gastroenterology* 2018;154:935-947
- Naganuma M, Aoyama N, Tada T, Kobayashi K, Hirai F, Watanabe K, Watanabe M, Hibi T. Complete mucosal healing of distal lesions induced by twice-daily budesonide 2-mg foam promoted clinical remission of mild-to-moderate ulcerative colitis with distal active inflammation: double-blind, randomized study. *J Gastroenterol.* 2018;53:494-506
- Fukuda T, Naganuma M, Sugimoto S, Ono K, Nanki K, Mizuno S, Kimura K, Mutaguchi M, Nakazato Y, Takabayashi K, Inoue N, Ogata H, Iwao Y, Kanai T. Efficacy of therapeutic intervention for patients with an ulcerative colitis Mayo Endoscopic Score of 1. *Inflamm Bowel Dis.* 2019; 14:782-788
- Naganuma M, Sugimoto S, Suzuki H, Matsuno Y, Araki T, Shimizu H, Hayashi R, Fukuda T, Nakamoto N, Iijima H, Nakamura S, Kataoka M, Tamura Y, Tatsumi K, Hibi T, Suzuki Y, Kanai T;

-
- INDIGO survey Group. Adverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey. *J Gastroenterol.* 2019;54:891-896
5. Mutaguchi M, Naganuma M, Sugimoto S, Fukuda T, Nanki K, Mizuno S, Hosoe N, Shimoda M, Ogata H, Iwao Y, Kanai T. Difference in the clinical characteristic and prognosis of colitis-associated cancer and sporadic neoplasia in ulcerative colitis patients. *Dig Liver Dis.* 2019;51:1257-1264.
 6. Yoshimatsu Y, Naganuma M, Sugimoto S, Tanemoto S, Umeda S, Fukuda T, Nomura E, Yoshida K, Ono K, Mutaguchi M, Nanki K, Mizuno S, Mikami Y, Fukuhara K, Sujino T, Takabayashi K, Ogata H, Iwao Y, Kanai T. Development of an indigo naturalis suppository for topical induction therapy in patients with ulcerative colitis. *Digestion.* 2019 Jun 25:1-7.
 7. Naganuma M, Hirai F, Kobayashi K, Watanabe K, Takeuchi K, Aoyama N. Middle-term prognosis in patients with ulcerative colitis who achieved clinical and endoscopic remission by budesonide rectal foam. *PLoS ONE* 2019;14: e0220413.
 8. Naganuma M, Kobayashi T, Nasuno M, Motoya S, Kato S, Matsuoka K, Hokari R, Watanabe C, Sakamoto H, Yamamoto H, Sasaki M, Watanabe K, Iijima H, Endo Y, Ichikawa H, Ozeki K, Tanida S, Ueno N, Fujiya M, Sako M, Takeuchi K, Sugimoto S, Abe T, Hibi T, Suzuki Y, Kanai T. Significance of conducting 2 types of fecal tests in patients with ulcerative colitis. *Clin Gastroenterol Hepatol.* 2019 Aug 5
 9. Naganuma M, Sugimoto S, Fukuda T, Mitsuyama K, Kobayashi T, Yoshimura N, Ohi H, Tanaka S, Andoh A, Ohmiya N, Saigusa K, Yamamoto T, Morohoshi Y, Ichikawa H, Matsuoka K, Hisamatsu T, Watanabe K, Mizuno S, Abe T, Suzuki Y, Kanai T, for the INDIGO Study Group. Indigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post-hoc analysis from the INDIGO study. *J Gastroenterol* 2019 Sep 16.
 10. Naganuma M, Yokoyama Y, Motoya S, Watanabe K, Sawada K, Hirai F, Yamamoto T, Hanai H, Omori T, Kanai T, Hibi T; CAPTAIN study Group. Efficacy of apheresis as maintenance therapy for patients with ulcerative colitis in an open-label prospective multicenter randomised controlled trial. *J Gastroenterol.* 2019 Dec 6.
 11. Hibi T, Naganuma M, Oda E, Yamada Y, Chujoh Y, Yoshihara R, Watanabe M. Predictive factors for achievement of mucosal healing by budesonide 2-mg foam in ulcerative colitis: a pooled analysis of data from two clinical trials. *Intest Res.* 2019 Dec 11.
-